Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial
- Generic Propofol Contamination Prompts Limited Recall
- Testing New Treatments For Severe H1N1 Infection
- Intrexon Corporation Initiates Phase 1b Clinical Trial In Advanced Melanoma
- Study Aims To Induce Recovery From Ankylosing Spondylitis
- Measurements Fail To Identify TB Patients Who Could Benefit From Shorter Treatment Course
- Chemical In Blood May Explain Susceptibility To Bladder Pain
- Celladon Provides MYDICAR(R) Program Update Of First-In-Human Trial For Advanced Heart Failure At American Society Of Gene Therapy Annual Meeting
- Full Testing Recommended For Medicinal Products Susceptible To 'Dose Dumping'
- Future Physicians Develop Conflict Of Interest Curriculum For Nation's Academic Medical Centers
Endocyte Announces Positive Results From A Phase II Clinical Study Of EC145 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Posted by: admin in Pharmacy Drugs on August 14th, 2009
Endocyte Inc., (http://www.endocyte.com/) a lung cancer (NSCLC).
Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.
“The data presented indicates the feasibility and promise of EC145 with EC20 imaging as targeted therapy for advanced non-small cell lung cancer,” said Martin J. Edelman, M.D., director of medical thoracic oncology at the University of Maryland Greenebaum Cancer Center and principal investigator for the study.
The primary objective for the clinical trial was to determine the percentage of patients who derived clinical benefit from therapy with EC145, where clinical benefit was defined as completing four months of therapy without disease progression. The study showed that at least 30 percent of all patients treated with EC145 achieved this threshold. EC20, a targeted molecular diagnostic imaging agent, was used to identify patients whose tumors expressed the folate receptor, the target of EC145. An analysis of EC20 positive patients receiving EC145 as third or fourth line therapy indicated a clinical benefit rate of 45 percent. Analysis of safety data indicated no significant bone marrow toxicity and that clinical benefit occurred in the context of relatively low toxicity for most patients.
The EC145 molecule uses folate to target the folate receptors found in high concentrations on the surface of tumors, including NSCLC, ovarian, renal and many other cancers. By binding directly to cells that overexpress folate receptors, EC145 delivers the anticancer agent directly to cancer cells while avoiding normal tissue.
“We are encouraged by the positive results that indicate treatment with EC145 may provide clinical benefit to a large percentage of patients with advanced-stage lung cancer,” said Richard Messmann, M.D., vice president of medical affairs at Endocyte. “As cancer care enters the age of personalized therapy, it is important to see drug pairs like EC20 and EC145 proceed to the next stage of clinical development. The idea of using a molecular diagnostic imaging agent like EC20 to select patients, followed by treatment with EC145, is exciting because doctors may be able to customize patient care in a way that has not occurred in the past. The fact that most patients who received EC145 also had minimal toxicity indicates that further clinical testing of the combination is clearly warranted.”
EC145 is also being evaluated in the PRECEDENT (http://www.endocyte.com/precedent/) trial, a randomized, international study evaluating the safety and efficacy of EC145 in combination with Doxil¨/Caelyx¨ in women with advanced ovarian cancer.
Endocyte is a privately held biotechnology company with headquarters in the Purdue Research Park, West Lafayette, Ind. Based on the applications of Endocyte’s advanced proprietary Drug Guidance System (DGS), the company is working to develop new drugs and companion diagnostic agents to treat many types of cancer and other serious diseases.
Source
Endocyte
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.